EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment

Yaqin Zhang, Yuanjiao Gao, Xinxin Li, Ziyu Zhang, Shiyu Wang, Zixuan Gao, Yao Xie, Minghui Li

Frontiers in Cellular and Infection Microbiology · 29.06.2026 · 16

DOI: 10.3389/fcimb.2026.1785154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 29.06.2026. Verfasst von Yaqin Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B e Antigens, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HBeAg seroclearance represents a critical milestone in the treatment of HBeAg-positive chronic hepatitis B (CHB), which is closely associated with disease remission, functional cure, and reduced hepatocellular carcinoma risk. As HBeAg is a secreted viral protein associated with active HBV replication, infectivity, and host immune tolerance, its disappearance usually indicates a transition toward improved immune control rather than simple loss of a laboratory marker. This review comprehensively explores the immunological mechanisms underlying HBeAg seroclearance, thoroughly examines its impact on the natural course of CHB and systematically analyzes the regulatory roles of antiviral drug efficacy, host immune status, and viral genotypes in HBeAg clearance. Integrating updated guidelines and evidence-based research, we propose optimized strategies for managing HBeAg-negative CHB, including goal setting, treatment cessation criteria, and long-term monitoring protocols. Our findings emphasize that HBeAg clearance not only signifies virological suppression but also reflects the dynamic equilibrium of host immune responses, thereby providing both theoretical foundation and practical support for achieving functional cure and reducing HCC risk in CHB patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B e AntigensAntiviral AgentsHepatitis B virusHumansCarcinoma, HepatocellularGenotypeLiver Neoplasms

Stichwörter der Autor:innen

HBeAgchronic hepatitis Bfunctional cureimmunetreatment

Substanzen

Hepatitis B e AntigensAntiviral Agents

Autor:innen und Institutionen

  • Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • HBV Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.

Förderung

  • National Key Research and Development Program of China
  • Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support

Zitieren

APA

Zhang, Y., Gao, Y., Li, X., Zhang, Z., Wang, S., Gao, Z., Xie, Y., & Li, M. (2026). The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1785154

Vancouver

Zhang Y, Gao Y, Li X, Zhang Z, Wang S, Gao Z, et al. The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1785154

BibTeX
@article{Zhang2026,
  author = {Zhang, Yaqin and Gao, Yuanjiao and Li, Xinxin and Zhang, Ziyu and Wang, Shiyu and Gao, Zixuan and Xie, Yao and Li, Minghui},
  title = {The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1785154}
}
Kostenlos starten →